Novel Treatment Receives FDA RMAT Designation in R/R Mantle Cell Lymphoma
Written by
Cancer Network
Published
0
comments
0
min
The anti-CD19/4-1BB CAR T-cell therapy candidate elicited an ORR and CR rate of 100% each in patients with relapsed/refractory MCL.